Torax Biosciences, a leading Northern Ireland life sciences and biomedical company, has launched a revolutionary new, clinically approved hand sanitiser proven to kill 99.99% of bacteria and viruses
ToraSan is a locally produced sanitiser formulated and developed by scientists to meet internationally recognised quality standards.
Products are manufactured under strict laboratory conditions at the company’s Newtownabbey headquarters, led by Managing Director and esteemed clinical researcher and published scientific author, Dr Lawrence McGrath PhD, MSc, T.D.
Dr McGrath explained: “Since the beginning of the pandemic we have seen a host of companies adapt their business to provide essential sanitisers in response to the urgent requirement for supply, particularly for frontline and key workers.
“As the threat persists, it is important that people continue to be vigilant and use a high-quality, clinically approved sanitiser capable of protecting everyone – from staff and customers to families and loved ones.
“ToraSan products are manufactured to the World Health Organisation’s recommended formulation with added Tea Tree Oil and are independently tested and verified to ensure the integrity of antibacterial and antiviral properties.”
ToraSan’s unique formula provides a minimum concentration of 75% isopropyl, certified by the World Health Organisation to provide the optimum level of protection against bacteria and viruses. Many hand sanitisers only provide between 60-70% alcohol concentration which can be incapable of killing viruses.
“ToraSan is formulated using isopropyl, which is the gold standard in antibacterial and antiviral defence. Not only does isopropyl provide optimal protection but it’s also kinder to skin. Ethanol-based sanitisers, whilst being potentially less effective, can also cause dry and cracked skin, or lead to more severe skin conditions with prolonged use. ToraSan also contains Tea Tree Oil, which helps protect the skin, providing its own well-known anti-inflammatory, antiseptic and antibacterial qualities”, continued Dr McGrath.
In addition, ToraSan is also available in 5 litre quantities in liquid and adapted gel for commercial use.
“Since we started developing this product we have been inundated with enquiries from distributors, pharmacies, retailers and commercial users. It is clear to us that consumers are becoming more educated in what products and formulations provide the optimum levels of protection and ToraSan offers the highest levels of protection on the market,” added Dr McGrath.
With a strong focus on research and development, the company is retaining all ToraSan profits to fund new scientific posts focused on research into the production of diagnostics for preeclampsia for use in developing countries where the condition can affect up to 16% of pregnancies  and is often fatal.
Established in 2014 and headquartered in Newtownabbey, Northern Ireland, Torax Biosciences is one of the fastest growing bioscience companies in the United Kingdom, exporting internationally to over 10 countries.
Torax Biosciences Ltd. designs, develops and manufactures in vitro diagnostic (IVD) reagents and novel quality controls for clinical laboratory use to inform the diagnosis of disease, guide clinical treatment and to mitigate or prevent future disease.
Last year, the company expanded its division of therapeutic areas to include infection prevention and control, providing a clinically approved hand sanitiser to the consumer market and incorporating a new e-commerce offering.
AS SEEN IN